At a glance
During this COCA Call, subject matter experts will provide an overview of COVID-19 epidemiology and the current variant landscape, address current Centers for Disease Control and Prevention testing guidance and the National Institutes of Health and Infectious Disease Society of America COVID-19 treatment guidelines, and discuss risk assessment and considerations for treatment options.
Overview
As SARS-CoV-2 variants evolve, circulating variants have increased transmissibility and ability to evade the immune system, which changes the treatment and prevention options for COVID-19. Clinicians should understand the nuances of current SARS-CoV-2 testing and treatment to prevent hospitalizations and deaths among people at high risk of severe disease.
During this COCA Call, subject matter experts will provide an overview of COVID-19 epidemiology and the current variant landscape, address current Centers for Disease Control and Prevention testing guidance and the National Institutes of Health and Infectious Disease Society of America COVID-19 treatment guidelines, and discuss risk assessment and considerations for treatment options.
Presenters
Pragna Patel, MD, MPH
CAPT, U.S. Public Health Service
Chief Medical Officer
COVID-19 Response
Centers for Disease Control and Prevention
Natalie Thornburg, PhD
Branch Chief of Lab Branch (Acting)
Coronavirus and Other Respiratory Viruses Division (Proposed)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Rajesh T. Gandhi, MD
Director, HIV Clinical Services and Education
Massachusetts General Hospital
Co-Director, Harvard Center for AIDS Research
Professor of Medicine, Harvard Medical School
Call Objectives
At the conclusion of the session, the participant will be able to accomplish the following:
- Cite background information on the topic covered during the presentation.
- Discuss CDC's role in the topic covered during the presentation.
- Describe the topic's implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.
Additional Resources
- People Who Are Immunocompromised
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States
- COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19
- FDA Paxlovid Patient Eligibility Screening Checklist for Providers
- HHS Therapeutics Homepage
- Test to Treat Initiative webpage and Fact Sheet
- Test to Treat Site Locator and Digital Tool Kit
- General Therapeutics Locator
- HHS Clinical Implementation Guide
- ASPR Regional Emergency Coordinators
- CMS reimbursement information for oral antivirals
- COVID-19/Therapeutics Updates
- CDC & FDA Identify Preliminary COVID-19 Vaccine Safety Signal for Persons Aged 65 Years and Older
Target Audience
- Physicians
- Nurses
- Pharmacists
- Veterinarians
- Physician Assistants
- Health Educators
- Other Clinicians
Additional Information
- Contact Information: coca@cdc.gov
- Support/Funding: Centers for Disease Control and Prevention, Emergency Risk Communication Branch
- Method of Participation: You may participate in the educational activity by viewing the program information above.